Sumitomo Pharma Co., Ltd.
Boost 2028: Accelerating a Strong Sumitomo Pharma
Sumitomo Pharma forecasts core sales of approximately 260 billion yen, core operating income of approximately 43 billion yen, and free cash flow of approximately 47 billion yen for FY2025, announcing a growth strategy targeting core product sales of 250 billion yen scale in the 2030s.
Key Figures
- Core 3 Product Sales: Approx. 260 billion yen (FY2025 forecast)
- Core Operating Income: Approx. 43 billion yen (FY2025 forecast)
- Equity Method Gain on Sale of Affiliates: 49 billion yen (Asian business restructuring)
AI要約
Advancement of Financial Goals and Growth Strategy
Sumitomo Pharma announced that it expects to achieve core 3 product sales of approximately 260 billion yen, core operating income of approximately 43 billion yen, and free cash flow of approximately 47 billion yen in FY2025, thereby advancing the financial targets set in Reboot 2027. The company will continue disciplined cost management of SG&A and R&D expenses to accelerate recovery-driven growth. A new mid-term management plan is planned, targeting sales of 250 billion yen for Orgovyx and 150 billion yen for Jemperli in the 2030s, while confirming direction for two oncology products.
Accelerating R&D and Business Growth
The company achieved approval application for the world’s first iPS cell-derived pharmaceutical in Japan and has started physician-initiated clinical trials in North America. Clinical trials for two oncology products are also advancing. Sales of Orgovyx and Jemperli are growing substantially in North America, and the Asian business was restructured to focus on core operations, recording an equity method gain of 49 billion yen. The company is strengthening promotion based on scientific evidence, emphasizing the intrinsic value of its products.
